Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Importance: Many patients with focal epilepsy experience seizures despite treatment with currently available antiseizure medications (ASMs) and may benefit from novel therapeutics. Objective: To evaluate the efficacy and safety of XEN1101, a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener, in the treatment of focal-onset seizures (FOSs). Design, Setting, and Participants: This phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging adjunctive trial investigated XEN1101 over an 8-week treatment period from January 30, 2019, to September 2, 2021, and included a 6-week safety follow-up. Adults experiencing 4 or more monthly FOSs while receiving stable treatment (1-3 ASMs) were enrolled at 97 sites in North America and Europe. Interventions: Patients were randomized 2:1:1:2 to receive XEN1101, 25, 20, or 10 mg, or placebo with food once daily for 8 weeks. Dosage titration was not used. On completion of the double-blind phase, patients were offered the option of entering an open-label extension (OLE). Patients not participating in the OLE had follow-up safety visits (1 and 6 weeks after the final dose). Main Outcomes and Measures: The primary efficacy end point was the median percent change from baseline in monthly FOS frequency. Treatment-emergent adverse events (TEAEs) were recorded and comprehensive laboratory assessments were made. Modified intention-to-treat analysis was conducted. Results: A total of 325 patients who were randomized and treated were included in the safety analysis; 285 completed the 8-week double-blind phase. In the 325 patients included, mean (SD) age was 40.8 (13.3) years, 168 (51.7%) were female, and 298 (91.7%) identified their race as White. Treatment with XEN1101 was associated with seizure reduction in a robust dose-response manner. The median (IQR) percent reduction from baseline in monthly FOS frequency was 52.8% (P < .001 vs placebo; IQR, −80.4% to −16.9%) for 25 mg, 46.4% (P < .001 vs placebo; IQR, −76.7% to −14.0%) for 20 mg, and 33.2% (P = .04 vs placebo; IQR, −61.8% to 0.0%) for 10 mg, compared with 18.2% (IQR, −37.3% to 7.0%) for placebo. XEN1101 was generally well tolerated and TEAEs were similar to those of commonly prescribed ASMs, and no TEAEs leading to death were reported. Conclusions and Relevance: The efficacy and safety findings of this clinical trial support the further clinical development of XEN1101 for the treatment of FOSs. Trial Registration: ClinicalTrials.gov Identifier: NCT03796962
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Self-citation
Cited by
Targeting Kv7 Potassium Channels for Epilepsy
Perucca, E., & Taglialatela, M. (2025) · CNS Drugs · doi:10.1007/s40263-024-01155-3 · Cited by 43
Self-citationWang, H., Qiao, Z., Luan, K., Xiang, W., Chang, X., Zhang, Y., Wei, N., & Wang, K. (2024) · Epilepsia · doi:10.1111/epi.18092 · Cited by 16
Butterfield, N. N., Luzon Rosenblut, C., Fava, M., Correll, C. U., Rothschild, A. J., Murrough, J. W., Mathew, S. J., Beatch, G. N., Grayson, C., Harden, C., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.14278 · Cited by 11
Self-citation
Metadata
- Authors
- French, J. A., Porter, R. J., Perucca, E., Brodie, M. J., Rogawski, M. A., Pimstone, S., Aycardi, E., Harden, C., Qian, J., Rosenblut, C. L., Kenney, C., Beatch, G. N., X-TOLE Study Group, Armstrong, R., Kutluay, E., Klein, P., Fakhoury, T., Liow, K., Flitman, S., Biton, V., Sperling, M., Kudrow, D., Jacobson, M., Detyniecki, K., Khan (Prev: Ramsay), F. A., Fertig, E., Ata, A. S., Naritoku, D., Abou-Khalil, B., Alick, S., Aboumatar, S., Callow (Prev: Moseley), S., Izadyar (Prev: Beach), S., Wechsler, R., Szaflarski, J., Fountain, N., Ali, I., Li, G., Rodgers-Neame, T., Waterhouse, E., Benbadis, S., Chung, S., Sam, M., Rogin, J., Segal, E., Steriade, C., Arain, A., Pellegrino, R., Laxer, K., Chachar, M., Nievera, C., Benzaquen, M., Gloss, D., Sadek, A., Zhang, L., Ma, W., Shah, A., Valeriano, J., Henninger, H., Tsai (Prev: Miller), J., Moseley, B., Kuzniecky, R., Shih, J., Cascino, G., Pinzon-Ardila, A., Gerard, E., Rashid, S., Uysal, U., Destefano, S., Tatum, W., Krishnaiengar (Prev: Bautista), S., Faught, R., Geller, E., Ania, R., Sethi, B., Phillips, B., Chatman, M., Segal(Satellite), E., Lerman, A., Zaher, N., Ayala, R., Gelfand, M., Lesch, D., Vossler, D., Lyons, P., Kuzniecky (Satellite), R., Steiner, D., del Campo, M., Clement, J.-F., Mirsattari, S., Connolly, M., Heath, C., Richardson, M., Hamandi, K., Galizia, E., White, K., Marson, A., Thomas, R., Steinhoff, B., Brandt, C., Lerche, H., Surges, R., Kellinghaus, C., Moeddel, G., Lehmann, R., Rosenow, F., Mayer, T., Schulze-Bonhage, A., Tilz, C., Toledo, M., Villanueva, V., Sanchez, J. C., Serrano-Castro, P., Rocamora, R., Saiz-Diaz, R. A., Centeno, M., Rodriguez-Uranga, J., Serratosa, J., Gil-Nagel (Prev: Aledo, A., Becerra, J. L., López-González, J., Campos, D., Sanchez, V., Simon-Talero, M., Garcia Morales, I., Toledano, R., Lisnic, V., Kharchuk, S., Aguglia, U., Galimberti, C., Canafoglia, L., Gambardella, A., Bisulli, F., Pizzanelli, C., Di Bonaventura, C., & Shakarishvili, R.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2023-11-01
- Volume
- 80
- Issue
- 11
- Pages
- 1145
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W4387439518
- Cited by
- 60
- References
- 1
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaneurol.2023.3542
- The paper
- French, J. A., Porter, R. J., Perucca, E., Brodie, M. J., Rogawski, M. A., Pimstone, S., Aycardi, E., Harden, C., Qian, J., Rosenblut, C. L., Kenney, C., Beatch, G. N., X-TOLE Study Group, Armstrong, R., Kutluay, E., Klein, P., Fakhoury, T., Liow, K., Flitman, S., . . . Shakarishvili, R. (2023). Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2023.3542
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.